News Release

November 6, 2024

Perseus Proteomics, Inc.
President & CEO: Takuya Yokokawa
e-mail: ir@ppmx.com

Announcement of Presentation of PPMX-T003 Phase I at 66th ASH Annual Meeting and Exposition

Perseus Proteomics Inc. is pleased to announce that the report of the phase I clinical trial of PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody, among polycythemia vera (PV) patients has been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held on December 7-10, 2024, in San Diego, California and online.

Title:	Phase I Safety Study of Anti-Transferrin Receptor 1 Antibody (PPMX-T003) in Patients with Polycythemia Vera and Erythrocythemia
Session Date/Time:	Monday, December 9, 2024, 6:00 PM – 8:00 PM (PST)
Abstract Number:	4542
Location:	San Diego Convention Center, Halls G-H

■ About PPMX-T003

PPMX-T003 is an antibody targeting TfR1 that is related to iron intake into cells. TfR1 is highly expressed in cells that require much more iron than usual cells. Erythroblasts, the precursors to red blood cells, are one of them. When PPMX-T003 binds to TfR1, it inhibits cell proliferation by inhibiting iron uptake into erythroblasts. Therefore, it is expected to normalize the number of RBCs of PV patients, characterized by an excessive number of RBCs.

TfR1 is also highly expressed in cancer cells that proliferate at a significant pace. PPMX-T003 similarly inhibits proliferation of cancer cells due to its function of inhibiting iron intake. Currently, investigator-led phase I/II clinical trial of PPMX-T003 among aggressive NK-call leukemia (ANKL) patients is underway.

■ About Perseus Proteomics

Perseus Proteomics is a biotech venture established in February 2001, aiming to develop novel antibody therapeutic drugs mainly for cancer. PPMX-T003 is a first-in-class TfR1 blocking antibody obtained from the library rich in diversity using the ICOS screening method (patent No. JPB4870348). The Company has been developing PPMX-T002, RI labelled antibody, and PPMX-T004, antibody drug conjugate (ADC), as well.
https://www.ppmx.com/en/

END